文献速递姑息放疗与转移瘤胸部肿瘤放疗

寡进展癌症的立体定向消融放疗:随机2期STOP试验结果

Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-08-19

该试验纳入≤5个寡进展转移灶且正在接受全身治疗的患者,按全身治疗类型分层后1:2随机分配至继续标准治疗或SABR联合标准治疗。90例患者中位随访31个月,SABR组与标准治疗组中位无进展生存期分别为8.4个月和4.3个月(P=0.91),中位总生存期分别为31.2个月和27.4个月(P=0.22),SABR组病灶控制率优于标准治疗组(70% vs 38%,P=0.0015)。

要点

  • SABR联合标准治疗组病灶控制率70%,优于标准治疗组的38%(P=0.0015)。
  • 两组中位无进展生存期分别为8.4个月和4.3个月(P=0.91),无差异。
  • SABR耐受良好,仅2例(3.4%)发生归因于SABR的3级不良事件,无4/5级事件。

核心结论

  • SABR耐受良好且病灶控制更优,但未改善无进展生存期或总生存期。
  • 研究入组困难,结果可能受到标准治疗组不愿放弃消融治疗的影响。

研究设计与样本

  • 随机2期试验,纳入1至5个正在接受全身治疗且进展的转移灶患者。
  • 按全身治疗类型(细胞毒性 vs 非细胞毒性)分层后,1:2随机分配至继续标准治疗或SABR联合标准治疗。
  • 试验最初限于非小细胞肺癌,后扩展至所有非血液系统恶性肿瘤以满足入组目标。
  • 共纳入来自8家加拿大机构的90例患者(127个寡进展转移灶),SABR组59例,标准治疗组31例。

主要发现

  • 中位年龄67岁,女性39例(43%),最常见原发部位为肺(44%)、泌尿生殖系统(23%)和乳腺(13%)。
  • 标准治疗组方案依从性欠佳,11例(35%)接受高剂量/消融治疗(与试验方案冲突)或退出研究。
  • 中位随访31个月,两组中位无进展生存期分别为8.4个月(SABR组)和4.3个月(标准治疗组),但曲线交叉,2年无进展生存率分别为9%和24%(P=0.91)。
  • 中位总生存期分别为31.2个月(SABR组)和27.4个月(标准治疗组)(P=0.22)。
  • 病灶控制率SABR组70% vs 标准治疗组38%(P=0.0015)。

关键数值与推荐

  • 主要终点为无进展生存期;次要终点包括总生存期、病灶控制、生活质量、不良事件及随机化后全身治疗持续时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 标准治疗组方案依从性欠佳,11例(35%)接受高剂量/消融治疗(与试验方案冲突)或退出研究。
  • 研究入组困难,结果可能受到标准治疗组不愿放弃消融治疗的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This trial examined if patients with ≤5 sites of oligoprogression benefit from the addition of SABR to standard of care (SOC) systemic therapy. METHODS AND MATERIALS: We enrolled patients with 1 to 5 metastases progressing on systemic therapy, and after stratifying by type of systemic therapy (cytotoxic vs noncytotoxic), randomized 1:2 between continued SOC treatment versus SABR to all progressing lesions plus SOC. The trial was initially limited to non-small cell lung cancer but was expanded to include all nonhematologic malignancies to meet accrual goals. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), lesional control, quality of life, adverse events, and duration of systemic therapy postrandomization. RESULTS: Ninety patients with 127 oligoprogressive metastases were enrolled across 8 Canadian institutions, with 59 randomized to SABR and 31 to SOC. The median age was 67 years, and 39 (43%) were women. The most common primary sites were lung (44%), genitourinary (23%), and breast (13%). Protocol adherence in the SOC arm was suboptimal, with 11 patients (35%) either receiving high-dose/ablative therapies (conflicting with trial protocol) or withdrawing from the study. The median follow-up was 31 months. There was no difference in PFS between arms (median PFS 8.4 months in the SABR arm vs 4.3 months in the SOC arm, but curves cross and 2-year PFS was 9% vs 24%, respectively; P = .91). The median OS was 31.2 months versus 27.4 months, respectively (P = .22). Lesional control was superior with SABR (70% vs 38%, respectively; P = .0015). There were 2 (3.4%) grade 3 and no grade 4/5 adverse events attributable to SABR. CONCLUSIONS: SABR was well-tolerated with superior lesional control but did not improve PFS or OS. Accrual to this study was difficult, and the results may have been impacted by an unwillingness to forgo ablative treatments on the SOC arm. (NCT02756793).

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Schellenberg D, Gabos Z, Duimering A, et al. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39168356. doi:10.1016/j.ijrobp.2024.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。